NO20080552L - GLP-1 farmasoytiske sammensetninger - Google Patents

GLP-1 farmasoytiske sammensetninger

Info

Publication number: NO20080552L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; glp; analogues; peptide; glucagon
Prior art date: 2005-06-30

Application number

NO20080552A

Other languages

English (en)

Norwegian (no)

Inventor

Zheng Xin Dong

Roland Cherif-Cheikh

Frederic Lacombe

Jose-Antonio Cordero Rigol

Resurreccion Alloza Miravete

Maria Dolores Tobalina Maestre

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-30

Filing date

2008-01-30

Publication date

2008-03-27

2008-01-30 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

2008-03-27 Publication of NO20080552L publication Critical patent/NO20080552L/no

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
241000124008 Mammalia Species 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20080552A 2005-06-30 2008-01-30 GLP-1 farmasoytiske sammensetninger NO20080552L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US69614205P	2005-06-30	2005-06-30
PCT/US2006/025826 WO2007005738A2 (fr)	2005-06-30	2006-06-30	Compositions pharmaceutiques de glp-1

Publications (1)

Publication Number	Publication Date
NO20080552L true NO20080552L (no)	2008-03-27

Family

ID=37605098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20080552A NO20080552L (no)	2005-06-30	2008-01-30	GLP-1 farmasoytiske sammensetninger

Country Status (13)

Country	Link
US (2)	US8236759B2 (fr)
EP (2)	EP1904525A4 (fr)
KR (1)	KR20080028981A (fr)
CN (1)	CN101258163B (fr)
AR (1)	AR055346A1 (fr)
AU (1)	AU2006265814B2 (fr)
CA (1)	CA2617859A1 (fr)
EA (1)	EA012287B1 (fr)
MX (1)	MX2008001468A (fr)
NO (1)	NO20080552L (fr)
NZ (1)	NZ565535A (fr)
TW (1)	TWI364292B (fr)
WO (1)	WO2007005738A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007340369C1 (en) *	2006-12-29	2013-05-02	Ipsen Pharma S.A.S.	GLP-1 pharmaceutical compositions
CA2687912C (fr) *	2007-06-08	2015-11-03	Janssen Pharmaceutica N.V.	Derives de piperidine/piperazine
JO2972B1 (en)	2007-06-08	2016-03-15	جانسين فارماسوتيكا ان. في	Piperidine / piperazine derivatives
RU2470017C2 (ru) *	2007-06-08	2012-12-20	Янссен Фармацевтика Н.В.	Производные пиперидина/пиперазина
CA2687918C (fr) *	2007-06-08	2016-11-08	Janssen Pharmaceutica N.V.	Derives de piperidine/piperazine
JP5579170B2 (ja)	2008-06-05	2014-08-27	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
EP2216042A1 (fr) *	2009-02-09	2010-08-11	Ipsen Pharma S.A.S.	Compositions pharmaceutiques analogues au GLP-1
PL3139948T3 (pl) *	2014-05-07	2020-08-10	Novo Nordisk A/S	Leczenie cukrzycy z zastosowaniem glp-1 i anty-il-21

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4591496A (en) *	1984-01-16	1986-05-27	Massachusetts Institute Of Technology	Process for making systems for the controlled release of macromolecules
US4810501A (en) *	1986-06-17	1989-03-07	Warner-Lambert Company	Sustained release pharmaceutical preparations
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
US5271945A (en) *	1988-07-05	1993-12-21	Takeda Chemical Industries, Ltd.	Sustained release microcapsule for water soluble drug
JP3277342B2 (ja) *	1992-09-02	2002-04-22	武田薬品工業株式会社	徐放性マイクロカプセルの製造法
TW333456B (en) *	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US6284727B1 (en) *	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
US5614487A (en) *	1993-05-28	1997-03-25	Genentech, Inc.	Sustained release pharmaceutical composition
US5705483A (en)	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (fr)	1993-12-09	1995-06-10	John A. Galloway	Peptites insulinotropiques agissant comme le glucagon, compositions et methodes
ATE178789T1 (de) *	1994-02-21	1999-04-15	Takeda Chemical Industries Ltd	Polyester matrix für eine pharmazeutische zusammensetzung mit verzögerter freigabe
US20010006943A1 (en) *	1994-12-23	2001-07-05	Ejvind Jensen	Protracted GLP-1 compositions
US6852690B1 (en)	1995-08-22	2005-02-08	Amylin Pharmaceuticals, Inc.	Method and composition for enhanced parenteral nutrition
US6006753A (en)	1996-08-30	1999-12-28	Eli Lilly And Company	Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk)	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (fr)	1996-11-12	2005-02-23	Novo Nordisk A/S	Utilisation de peptides glp-1
US6380357B2 (en)	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
WO1999043705A1 (fr)	1998-02-27	1999-09-02	Novo Nordisk A/S	Derives de glp-1 tronques a l'extremite n-terminale
ATE230274T1 (de)	1998-03-20	2003-01-15	Takeda Chemical Industries Ltd	Physiologisch aktives polypeptid enthaltende zubereitung mit verzögerter freisetzung und deren herstellung
SE9802080D0 (sv)	1998-06-11	1998-06-11	Hellstroem	Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
RU2205188C2 (ru)	1998-06-30	2003-05-27	Ново Нордиск А/С	Затравочные кристаллы для получения пептидов или протеинов
JP2002523333A (ja)	1998-07-31	2002-07-30	ノボノルディスクアクティーゼルスカブ	Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
MY155270A (en)	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
SG125915A1 (en) *	1998-12-07	2006-10-30	Sod Conseils Rech Applic	Analogues of glp-1
JP4548623B2 (ja) *	1999-02-24	2010-09-22	多木化学株式会社	生体材料
US6506724B1 (en)	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
AU5760900A (en)	1999-06-25	2001-01-31	Minimed, Inc.	Multiple agent diabetes therapy
US6458387B1 (en) *	1999-10-18	2002-10-01	Epic Therapeutics, Inc.	Sustained release microspheres
US6569832B1 (en)	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
DK1246638T4 (da)	2000-01-10	2014-09-22	Amylin Pharmaceuticals Llc	Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
US6844321B2 (en)	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
WO2001057084A1 (fr)	2000-01-31	2001-08-09	Novo Nordisk A/S	Cristallisation d'un analogue de glp-1
WO2001068112A2 (fr)	2000-03-14	2001-09-20	Goeke Burkhard	Effets du peptide-1 (7-36) similaire au glucagon sur la motilite antro-pyloro-duodenale
WO2001089554A2 (fr)	2000-05-19	2001-11-29	Bionebraska, Inc.	Traitement du syndrome coronarien aigu par glp-1
BR0111562A (pt) *	2000-06-16	2003-04-15	Lilly Co Eli	Análogos de peptìdeo 1 semelhantes ao glucagon
US6528520B2 (en)	2000-08-15	2003-03-04	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
CA2420550A1 (fr)	2000-08-24	2002-02-28	Thomas Jefferson University	Nouveau peptide possedant des effets sur la sante cerebrale
NZ519752A (en)	2000-10-20	2005-04-29	Amylin Pharmaceuticals Inc	Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7259233B2 (en)	2000-12-13	2007-08-21	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2002048192A2 (fr) *	2000-12-13	2002-06-20	Eli Lilly And Company	Glp-1 amide
CZ2004441A3 (cs)	2001-10-01	2004-11-10	Eli Lilly And Company	Léčivo pro snižování mortality a morbidity souvisejících s kritickými onemocněními
US20050053588A1 (en)	2001-10-18	2005-03-10	Li Yin	Conversion of liver stem and progenitor cells to pancreatic functional cells
US7179788B2 (en)	2001-10-19	2007-02-20	Eli Lilly And Company	Biphasic mixtures of GLP-1 and insulin
WO2003059378A2 (fr)	2001-12-29	2003-07-24	Novo Nordisk A/S	Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
US7105489B2 (en)	2002-01-22	2006-09-12	Amylin Pharmaceuticals, Inc.	Methods and compositions for treating polycystic ovary syndrome
US20030199445A1 (en)	2002-02-07	2003-10-23	Knudsen Lotte Bjerre	Use of GLP-1 compound for treatment of critically ill patients
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
US6969702B2 (en)	2002-11-20	2005-11-29	Neuronova Ab	Compounds and methods for increasing neurogenesis
US20040209803A1 (en)	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
CA2550695A1 (fr)	2003-12-16	2005-06-30	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R	Compositions pharmaceutiques glp-1
US7456254B2 (en) *	2004-04-15	2008-11-25	Alkermes, Inc.	Polymer-based sustained release device
HRP20110831T1 (hr) *	2004-04-15	2012-01-31	Alkermes Pharma Ireland Limited	Oblik za produljeno oslobađanje na bazi polimera
US7323169B2 (en) *	2004-04-23	2008-01-29	Amgen Inc.	Sustained release formulations
JP5000493B2 (ja)	2004-05-20	2012-08-15	ディアメディカインコーポレイテッド	インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット

2006
- 2006-06-30 EP EP06774416A patent/EP1904525A4/fr not_active Withdrawn
- 2006-06-30 CN CN200680031646XA patent/CN101258163B/zh not_active Expired - Fee Related
- 2006-06-30 EP EP12150837A patent/EP2441460A1/fr not_active Withdrawn
- 2006-06-30 MX MX2008001468A patent/MX2008001468A/es unknown
- 2006-06-30 KR KR1020087002509A patent/KR20080028981A/ko not_active Ceased
- 2006-06-30 AR ARP060102840A patent/AR055346A1/es not_active Application Discontinuation
- 2006-06-30 CA CA002617859A patent/CA2617859A1/fr not_active Abandoned
- 2006-06-30 NZ NZ565535A patent/NZ565535A/en not_active IP Right Cessation
- 2006-06-30 US US11/479,074 patent/US8236759B2/en not_active Expired - Fee Related
- 2006-06-30 WO PCT/US2006/025826 patent/WO2007005738A2/fr not_active Ceased
- 2006-06-30 AU AU2006265814A patent/AU2006265814B2/en not_active Ceased
- 2006-06-30 TW TW095124004A patent/TWI364292B/zh not_active IP Right Cessation
- 2006-06-30 EA EA200800181A patent/EA012287B1/ru not_active IP Right Cessation
2008
- 2008-01-30 NO NO20080552A patent/NO20080552L/no not_active Application Discontinuation
2012
- 2012-07-09 US US13/544,035 patent/US20120277151A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2006265814A1 (en)	2007-01-11
EA200800181A1 (ru)	2008-06-30
AR055346A1 (es)	2007-08-22
US20070021339A1 (en)	2007-01-25
CA2617859A1 (fr)	2007-01-11
TWI364292B (en)	2012-05-21
TW200740456A (en)	2007-11-01
EP1904525A2 (fr)	2008-04-02
US20120277151A1 (en)	2012-11-01
NZ565535A (en)	2011-03-31
EP1904525A4 (fr)	2009-10-21
CN101258163A (zh)	2008-09-03
EA012287B1 (ru)	2009-08-28
AU2006265814B2 (en)	2012-05-10
US8236759B2 (en)	2012-08-07
KR20080028981A (ko)	2008-04-02
WO2007005738A3 (fr)	2007-09-13
CN101258163B (zh)	2013-08-21
EP2441460A1 (fr)	2012-04-18
MX2008001468A (es)	2008-04-07
WO2007005738A2 (fr)	2007-01-11

Publication	Publication Date	Title
SA521431209B1 (ar)	2024-08-05	مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
ATE541582T1 (de)	2012-02-15	Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
CY1118007T1 (el)	2017-05-17	Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων
NO20100307L (no)	2001-08-06	GLP-1 analoger
GEP20084439B (en)	2008-07-25	Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
EA201000399A1 (ru)	2011-02-28	Композиции и способы использования проостровковых пептидов и их аналогов
MX2009002666A (es)	2009-04-09	Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos.
UA96308C2 (ru)	2011-10-25	Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2005058252A3 (fr)	2006-08-31	Compositions pharmaceutiques glp-1
EA200802058A1 (ru)	2009-06-30	Производные циклоалкиламинокислот и их фармацевтические композиции
ATE522226T1 (de)	2011-09-15	Verfahren und zusammensetzungen zur behandlung des polyzystischen ovarialsyndroms
NO20074823L (no)	2007-11-16	Rasagilin-formuleringer med forbedret innholdsensartethet
TW200745078A (en)	2007-12-16	Isoindole-imide compounds and compositions comprising and methods of using the same
MA32812B1 (fr)	2011-11-01	Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
ATE554084T1 (de)	2012-05-15	N-hydroxyacrylamidverbindungen
WO2004074315A3 (fr)	2004-11-25	Analogues de glp-1
EA200900373A1 (ru)	2009-10-30	Реконструированные сурфактанты, обладающие улучшенными свойствами
BRPI0509074A (pt)	2007-08-21	composições farmacêuticas compreendendo agonistas do receptor da tiróide
CA3120794C (fr)	2025-11-25	Formulations d'analogues peptidiques d'oxyntomoduline
NO20053111L (no)	2005-08-24	Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
WO2008103378A3 (fr)	2008-12-18	Méthodes de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
EA200900985A1 (ru)	2009-12-30	Способ получения оптически чистого омепразола
UA97348C2 (en)	2012-02-10	HETEROCYCLIC NF-kB INHIBITORS
CY1109803T1 (el)	2014-09-10	Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση

Legal Events

Date	Code	Title	Description
2014-02-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application